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ABSTRACT: The aim of this study was to fabricate novel microparticles (MPs) for
efficient and long-term delivery of amikacin (AMI). The emulsification method
proposed for encapsulating AMI employed low-molecular-weight poly(lactic acid)
(PLA) and poly(lactic acid-co-polyethylene glycol) (PLA−PEG), both supplemented
with poly(vinyl alcohol) (PVA). The diameters of the particles obtained were
determined as less than 30 μm. Based on an in-vitro release study, it was proven that
the MPs (both PLA/PVA- and PLA−PEG/PVA-based) demonstrated long-term
AMI release (2 months), the kinetics of which adhered to the Korsmeyer−Peppas
model. The loading efficiencies of AMI in the study were determined at the
followings levels: 36.5 ± 1.5 μg/mg for the PLA-based MPs and 106 ± 32 μg/mg for
the PLA−PEG-based MPs. These values were relatively high and draw parallels with
studies published on the encapsulation of aminoglycosides. The MPs provided
antimicrobial action against the Staphylococcus aureus, Escherichia coli, Pseudomonas
aeruginosa, and Klebsiella pneumoniae bacterial strains. The materials were also
comprehensively characterized by the following methods: differential scanning calorimetry; gel permeation chromatography;
scanning electron microscopy; Fourier transform infrared spectroscopy−attenuated total reflectance; energy-dispersive X-ray
fluorescence; and Brunauer−Emmett−Teller surface area analysis. The findings of this study contribute toward discerning new
means for conducting targeted therapy with polar, broad spectrum antibiotics.
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1. INTRODUCTION
Amikacin (AMI) is a semisynthetic, broad spectrum amino-
glycoside antibiotic, primarily used against infections caused by
Gram-negative bacteria. Examples include Escherichia coli,
potentially resulting in diseases affecting the digestive and
urinary systems, or Klebsiella pneumoniae and Pseudomonas
aeruginosa, which trigger nosocomial infections. AMI is less
commonly applied against infections precipitated by Gram-
positive bacteria such as Staphylococcus epidermidis or Staph-
ylococcus aureus, both constituting sources of post-hospital
infections.1
Despite its therapeutic action, AMI is known to have toxic side
effects, especially nephrotoxicity and ototoxicity due to its low
therapeutic index. Another drawback relates to poor absorption
if administered orally, as a consequence of the polycationic
nature of the molecule. For these reasons, medicating with AMI
has to be a strictly controlled process.2,3
AMI consists of D-glucosamine and D-kanosamine connected
with aminocyclitol by glycosidic bonds (Figure 1). It exhibits
high polarity and hydrophilicity (the logarithm of the partition
coefficient is equal to −7.40), as well as high solubility in water
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Figure 1. Structure of AMI.
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(185 g/L, 25 °C), slight solubility in methanol, and marked
insolubility in other organic solvents. Its mean values of
constants for acid and basic dissociation are 12.1 and 9.79,
respectively.
Polymer-based systems for targeted drug delivery have been
widely researched in recent years. They permit dosage of a high
concentration of the active substance, localized in the designated
tissue at a specific time, without exceeding levels of systemic
toxicity. Additionally, it is possible to tailor a polymer matrix to
exhibit specific kinetics of release, thereby personalizing therapy
for patients. The benefit of this is reduction in the frequency of
dosage and mitigation of side effects. Such advantages are
especially important and desirable for treatment with AMI.
Microparticles (MP, herein singular and plural) are polymer
carriers suitable for use as drug delivery systems. FabricatingMP
facilitates encapsulation of the drug molecules within a so-called
polymer cage. This not only means the molecules of the active
substance are protected physically but the potential also exists
for customizing the kinetics of drug release, depending on
physicochemical properties of the given materials. The most
common procedure for encapsulation involves evaporating
solvents in an aqueous emulsion (e.g., water/oil or water/oil/
water emulsions). Therefore, the solutions of the drug and
polymer are solidified through creatingMP (see Figure S1). The
fabrication methods are relatively simple and easily performed
on an industrial scale.
Either natural or synthetic polymers are applicable for
encapsulating a medicinal drug. Examples of the former include
proteins, polysaccharides, and peptides, for example, alginate/
chitosan particles suitable for hydrophobic drugs such as
quercetin4 and proteases.5 As for synthetic polymers, those
commonly employed comprise poly(lactic acid) (PLA), a
copolymer of poly(lactic acid) and poly(ethylene glycol)
(PLA−PEG), and poly(lactic-co-glycolic acid) (PLGA), the
latter of which can encapsulate proteins.6
Out of these materials, PLA and PLA−PEG make for highly
efficient drug carriers with sustainable and long-term release,
bolstered by their properties of biocompatibility, biodegrad-
ability (by hydrolysis and enzymatic reactions) without risk of
hazardous products, general availability, and affordability.7,8
Another notable aspect is that PLA is approved by the Food and
Drug Administration for medical use.7
Some PLA- or PLGA-based systems loaded with aminoglyco-
sides (including AMI) have been reported in the literature,9−16
and the ones most widely employed aid in the treatment of
respiratory infections and osteomyelitis.9,10,12−16 It is worth
noting, however, that those loaded with aminoglycosides are
difficult to fabricate because of the hydrophobic character of the
polymers employed, for example, PLA. The reason is that during
emulsification, greater affinity for the drug exists in the external
aqueous phase than that for the polymer (Figure S1).
Encapsulation heightens the stability of the material structure
during treatment and allows for controlled, extended, and
gradual release of the active substance, due to the occurrence of
degradation and/or swelling in a hydrolytic environment.
As far as the authors are aware, only a few studies have been
published on AMI encapsulation within a synthetic polymer.
The first study utilized Eudragit RS100 and RL100 polymers and
was dedicated to the delivery of an ocular drug.17 Another
investigated alginate nanoparticles with modified PLGA had
been loaded with both AMI and moxifloxacin for the treatment
of tuberculosis.18 A study by Sabaeifard et al. presented a
procedure for encapsulating AMI in PLGA nanoparticles as a
drug carrier for treating infections caused by P. aeruginosa,
reporting a loading efficiency (LE) of 26.0 ± 1.3 μg/mg.9,16 In
comparison with these,9,16,17 the proposed means of encapsulat-
ing AMI detailed herein utilizes low-molecular-weight PLA and
PLA−PEG supplemented with poly(vinyl alcohol) (PVA) by
W/O/W emulsification. The authors concentrated on develop-
ing materials with a broad spectrum of antibacterial activity and
controlled kinetics of drug release. The novel materials are
suitable for medicating against nosocomial infections (including
postoperative wounds) and numerous bacterial infections (such
as sepsis or tuberculosis). The form of the material, that is, MPs,
facilitates the application directly on the infected tissue, for
example, via a dressing with an appropriately selected dose of
AMI-loaded MP, or through administration of an dosed aerosol.
The unquestionable advantage consists in the versatile forms of
administration, especially in hospital treatment, where infections
of various tissues occur.
This study details the comprehensive research conducted on
the properties of the fabricated materials, including their
antimicrobial action and kinetics of in vitro drug release, as
well as characterization of their morphology and elemental
analysis.
2. EXPERIMENTAL SECTION
2.1. Materials. The following were used: amikacin (AMI)
disulfate (Interquim); lactic acid (LA) 80% water solution
(Merck); tin(II) 2-ethylhexanoate [Sn(Oct)2] (Sigma-Aldrich);
deionized water; poly(ethylene oxide) (PEG) (Mw = 380÷420
g/mol) (Merck); PVA 80% hydrolyzed (Mw = 9000 ÷ 10,000 g/
mol) (Merck); chloroform (Chromspec); acetone; methanol
(MeOH); acetonitrile (ACN); tetrahydrofuran-stabilized BHT
(THF) (Merck); ammonium acetate (Sigma-Aldrich); o-
phthaldialdehyde (OPA); acetic acid; boric acid (Sigma-
Aldrich); sodium hydroxide; potassium hydroxide; sodium
chloride; potassium chloride; dipotassium phosphate (Lach-
Ner); and monosodium dihydrogen orthophosphate (PENTA).
Polystyrene standards [for gel permeation chromatography
(GPC)] equaled 580 ÷ 6,000,000 g/mol (Polymer Laboratories
Ltd.)
The following bacterial strains (Tomas Bata University in
Zliń, Czech Republic) were used: S. aureus CCM 4516; E. coli
CCM 4517; Enterococcus faecalis CCM 3956; K. pneumoniae
CCM 4415; and P. aeruginosa CM 1961.
2.2. Synthesis of PLA and PLA−PEG. The PLA was
synthesized, according to a procedure derived from a method
described by Pavelkova et al.19 In brief, 100 mL of the LA
monomer was poured into a round-bottom two-neck distilling
flask that was then connected to a condenser. The mixture was
formulated by a dehydration phase stirred in an oil bath at 160
°C under reduced pressure, at 20 kPa for 4 h, and 0.5% w/w of
Sn(Oct)2 was added in afterward. The pressure was sub-
sequently reduced to 3 kPa, and the reaction continued for 24 h.
The product of the polycondensation reaction was precipitated
with MeOH and water, purified with acetone, and dried in a
vacuum oven.
The synthesis of the PLA−PEG was analogous to that
described for the PLA, except 10% w/w PEG and 0.5% w/w of
Sn(Oct)2 were added in after dehydration. All subsequent steps
were identical.
2.3. Preparation of the PLA/PVA-AMI and PLA−PEG/
PVA-AMI MPs. 2% w/v of the synthesized PLA or PLA−PEG
was dissolved in chloroform overnight. 15 mL of the resultant
polymeric solution was supplemented with 2.5 mL of 2.5% w/v
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AMI water solution, added dropwise under sonication in an ice
bath. The primary emulsion was sonicated for 25 min, following
which 100mL of 1%w/v PVA solution was gradually added into
it over the course of an hour. The solution was mixed overnight
to evaporate the chloroform and stabilize the particles. The
suspension obtained was centrifuged (15 min, 9000 rpm) and
washed with deionized water three times, frozen overnight, and
lyophilized (Figure S2).
2.4. Characterization. 2.4.1. Differential Scanning Calo-
rimetry. Characterization of the synthesized PLA and PLA−
PEG was carried out on a DSC1 differential scanning
calorimeter (Mettler Toledo). The temperature cycle was set
as follows: heating from −35 to 200 °C (rate: 10 °C/min), then
2 min heating at 200 °C, and cooling to −35 °C (rate: 10 °C/
min); this was repeated after 2 min of maintained temperature.
This procedure for the measurement occurred under a nitrogen
atmosphere.
2.4.2. Gel Permeation Chromatography. GPC analysis was
performed to characterize the synthesized PLA and PLA−PEG
and study the degradation of the MP, so as to discern loss in
mass in an aqueous environment. GPC transpired as follows:
three connected LC columns were usedPL gel MIXED-A
(300 × 7.8 mm, 20 μm) + MIXED-B (300 × 7.8 mm, 10 μm) +
MIXED-D (300 × 7.8 mm, 5 μm); THF was applied as a mobile
phase at the flow rate of 1 mL/min; separation was carried out at
the established temperature of 40 °C; and the injection volume
equaled 100 μL. For detection purposes, a refractive index
detector and viscometric detector were employed. The
calibration curves were plotted, according to polystyrene
standards (580 ÷ 6,000,000 g/mol, Polymer Laboratories Ltd.,
UK).
2.4.3. Scanning Electron Microscopy. Scanning electron
microscopy (SEM) micrographs of the unloaded and loaded
polymer systems (MP of PLA/PVA andMP of PLA−PEG/PVA
before and after AMI encapsulation) were obtained on a Nova
NanoSEM 450 scanning electron microscope set to 5 kV. The
samples were placed on the carbon tape and coated with a
sputtered gold/palladium layer (SC7620 Mini Sputter Coater,
Quorum Technologies).
2.4.4. Fourier Transform Infrared Spectroscopy−Attenu-
ated Total Reflectance. Fourier transform infrared spectrosco-
py−attenuated total reflectance (FTIR−ATR) analysis was
conducted to gauge whether interaction occurred between the
AMI and polymer carriers, on a Nicolet iS5 FTIR spectrometer
equipped with an iD5 ATR accessory, at the resolution of 4
cm−1, across 64 scans and with Ge as the optical material. The
series of analyzed samples comprised AMI sulfate standard
(powder), MP of PLA/PVA with and without AMI, and MP of
PLA−PEG/PVA with and without AMI.
2.4.5. Elemental Analysis. Elemental studies of the prepared
materials as powder were performed via energy-dispersive X-ray
fluorescence (EDXRF), on a Thermo Scientific ARL Quant X
spectrometer. Measurements were taken for CHO, Al, Ca, S, Cl,
Mg, K, and Sn; the samples were analyzed in the He
measurement mode.
The FLASH analytical method was employed for determining
the percentage of C, H, N, O, and S. The destructive Dumass
combustion method was applied (960 °C), and the products
(CO2, N2, H2O, and SO2) of the catalytic reaction were analyzed
by gas chromatography with thermal conductivity detection
(GC-TCD); the resulting values are given in percent by weight
(%w/w). Sulfanilamide was used as a standard. Each sample was
prepared in triplicate, and twomeasurements were conducted to
determine the value for SD.
2.4.6. Brunauer−Emmett−Teller Surface Area Analysis.
Analysis of the surface and porosity of the materials took place
on a Micrometrics Brunauer−Emmett−Teller (BET)-Method-
surface device (Belsorp-mini II, BEL Japan, Inc.). Prior to taking
measurements for the MP of PLA/PVA-AMI and PLA−PEG/
PVA-AMI, the samples were degassed for 3 h at 40 °C.
2.4.7. Thermogravimetric Analysis. The thermal stability of
the materials (MPunloaded and loaded) was established
through thermogravimetric experiments conducted on a
thermogravimetric analysis (TGA) Q500 unit (TA Instruments,
New Castle, USA) under a nitrogen atmosphere. The heating
rate was 10 °C per 1 min, while the range in temperature
encompassed 25−500 °C.
2.4.8. Microbiological PropertiesDisk Diffusion Method
(Kirby−Bauer Method). Equal masses of the samples (AMI
sulfate and MP with and without AMI) were placed on
inoculated Mueller-Hinton agar (two samples per Petri dish)
and incubated at 35 °C for 18−24 h. After incubation, the width
of the inhibition zone for each sample was measured to the
nearest millimeter on a SCAN 500 inhibition zone reader
(version 8.2.0.0). The samples were analyzed in triplicate.
Testing was performed on the bacterial strains of S. aureus
CCM 4516, E. coli CCM 4517, E. faecalis CCM 3956, K.
pneumoniae CCM 4415, and P. aeruginosa CM 1961; the
concentration of the bacterial suspensions equaled 106−107 cfu/
mL.
2.4.9. High-Performance Liquid Chromatography. High-
performance liquid chromatography (HPLC) was carried out
for determination of AMI, utilizing “in-needle” derivatization
with OPA reagent and fluorescence detection (HPLC Dionex
UltiMate 3000 Series, Thermo Fisher Scientific).
The stock solution of AMI (1 mg/mL) was prepared in
deionized water and stored at −20 °C. Working standard
solutions (0.5, 1, 5, 10, 25, 50, and 100 μg/mL) were prepared
daily by diluting the stock solution with phosphate-buffered
saline (PBS, pH = 7.4). The PBS was prepared by dissolving 8 g
of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of KH2PO4
in 1 L of distilled water, and the pH of the buffer was adjusted to
7.4 by NaOH.
Chromatographic separation was carried out using Waters
XSELECT CSH C18 (4.6 × 250 mm, 5 μm) column equipped
with a security guard column (Phenomenex) at 30 °C. A mobile
phase mixture of 100 mM acetate buffer (pH 5.8, eluent A) and
ACN (eluent B) was used under isocratic conditions (55:45 v/
v) at a flow rate of 0.4 mL/min; the duration of analysis was 20
min, and the sampler was set to 7 °C. The volume of the
injection was defined by user-defined program settings; 10 μL
was injected into the column which originated from a drawn
sample volume of 1 μL.
The reagents introduced into the needle during derivatization
comprised 1 μL of sample, 5 μL of borate buffer (I), 3 μL ofOPA
reagent (III), and 1 μL of 1 M acetic acid, where
I Buffer solution: 5 g of H3BO3 + 90 mL of H2O; made up
to the volume of 100 mL with KOH 47% to pH 11
II Reducing solution: 250 μL of 2-mercaptoethanol + 10mL
of buffer solution (I)
III OPA reagent: 2.5 mg of OPA + 400 μL of MeOH + 200
μL of reducing solution (II) + 4.4 mL of buffer solution
(I)
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Detection was conducted with 330 and 440 nm as the
excitation and emission wavelengths, respectively. An external
calibration method was applied to quantify the AMI. The
calibration curve obtained was linear (R2 = 0.9994) within the
given ranges of the concentration. The limits of detection (LOD
= 3.3× calibration curve intercept standard deviation divided by
the slope of the calibration curve) and the limits of quantitation
(LOQ= 3× LOD) were established as follows: LOD= 0.19 μg/
mL and LOQ = 0.58 μg/mL.
2.4.10. In Vitro Release Study into Liquid Media. For the
release test, 50 mg of the MP were immersed in 10 mL of PBS
(pH 7.4). The samples were incubated at 37 °C with gentle
shaking (100 rpm). 1 mL of the liquid fraction of each sample
was collected (at a specific time) and replaced with a portion of
fresh buffer. Each sample was prepared in triplicate and analyzed
three times by HPLC. The test was carried out under sink
conditions, whereby AMI was characterized by complete
solubility under the applied conditions.
Liquid fractions following preparation of the MP were also
investigated to gauge their encapsulation efficiency (% EE, eq 1)
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where Ctthe total amount of AMI used to modify the MP
(mg); Cfthe amount of excess AMI in the waste solution after
the material had been prepared (mg); and Wmthe weight of
the dry mass of the prepared material (mg).
The cumulative release (CR) and cumulative release in
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where C0the amount of AMI loaded (mg).
The kinetics of AMI release were also researched. In this
context, the release constant K was established through different
mathematical modelszero-order kinetics (eq 5), first-order
kinetics (eq 6), the HiguChi square root model (eq 7), and the























where CRfinthe total amount of AMI released (mg); Kthe
release constant; nthe diffusion coefficient (where n ≤ 0.45
represents Fickian diffusion, and 0.45 < n < 1 is the characteristic
for anomalous transport20).
3. RESULTS AND DISCUSSION
3.1. Characterization of the Synthesized PLA and
PLA−PEG.Determining the primary properties of the prepared
PLA and PLA−PEG after synthesis (polycondensation) was
performed by differential scanning calorimetry (DSC; the results
are given in Table 1) and GPC.
The PLA−PEG copolymer exhibited reduction in thermal
stability compared to PLA, in addition to which crystallization
for the former occurred at a temperature of less than 10 °C,
unlike the latter, and its content of the crystalline phase was
higher by approximately 15 J/g.
Upon further analysis, it was noted that the PLA−PEG
copolymer demonstrated a lower glass-transition temperature
(Tg) than PLA, potentially caused by the low Tg value for pure
PEG in comparison to PLA.21,22 Also of interest was a decrease
in Tg attributed to a drop in the molecular weight and rise in the
number of functional groups at the end of the polymer chain;
hence, a reduced value of Tg for the synthesized PLA−PEG
copolymer was recorded (see Table 1).19 Adding PEG raised the
values of ΔHm and ΔHc, a finding reported in the literature as
possibly pertaining to increase in the crystallinity of the resultant
copolymer.21,23,24 Such heightened crystallinity due to the
presence of PEGmay slow down the release of the drug from the
polymer matrix, although PEG also has the effect of raising the
amphiphilicity of the material and, subsequently, the affinity of
AMI for the polymer matrix (i.e., an increase in LE). An
additional consequence of supplementing with PEG is that the
reduction in Tg could positively affect the degradation of the
polymer at the stage of synthesis of the MP and their use
afterward (see the degradation study in the following section and
Table 10).
As for other considerations related to the crystallization
process, it should be noted that the literature states that
aminoglycosides, such as AMI, do not significantly affect the
crystallization of PLA- and PEG-based materials.24 Therefore,
only the PLA and PLA−PEG polymers (after synthesis)
underwent DSC.
A review of the literature revealed that the masses of PLA
material prepared by polycondensation varied, according to the
given reaction conditions, especially the type of catalyst
employed. In this context, the values of number average molar
masses (Mn) for PLA reported therein ranged from 2000−8000
g/mol, these being directly affected by the catalyst used.25 The
intention of the authors of this study was to obtain materials of a
relatively low-molecular weight (3000−4000 g/mol), and a
modified methodology described by Pavelkova et al. was
investigated for this express purpose.19 They prepared a PLA
copolymer with 7.5% w/w PEG and a number average molar
mass (Mn) of 3200 g/mol. The material, after modification, was
Table 1. DSC Results for the Synthesized PLA and PLA−
PEGa
sample Tg (°C) Tm (°C) ΔHm (J/g) Tc (°C) ΔHc (J/g)
PLA 41.1 143.4 43.5 94.5 19.9
PLA−PEG 32.5 139.3 44.7 84.7 34.4
aTgtemperature of glass transition; Tmmelting point; ΔHm
enthalpy of fusion; Tctemperature of crystallization; and ΔHc
enthalpy of crystallization.
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capable of controlled delivery of a bioactive agent (metaza-
chlor). Table 2 summarizes the GPC results obtained herein for
the given synthesized materials, showing that PLA and the PLA
copolymer with 10%w/w PEG possessed number averagemolar
masses (Mn) of 3000 and 2800 g/mol, respectively.
The materials (PLA and PLA−PEG) were both applied to
obtain MP loaded with AMI.
3.2. MPs Loaded with AMI: PLA/PVA-AMI and PLA−
PEG/PVA-AMI. The MP loaded with AMI were prepared via
the water/oil/water (W1/O/W2) emulsion method, utilizing
AMI (W1) and PVA (W2) aqueous solutions and PVA as the
surfactant. It has been reported in the literature that PLA
supplemented with PVA enhances the properties of PLA-based
materials through increase in hydrophilicity and ductility.26 The
organic component (O) consisted of PLA or PLA−PEG in
chloroform.
A preliminary study investigated a methodology described by
Rafat et al. on MP based on PLA−PEG and loaded with
protein27 to determine the potential it had for fabricating
materials with AMI (see Supporting Information: description of
initial conditions for preparation of the MPs). SEMwas conducted
to characterize the prepared MP at the outset, the images
revealing the MP prepared with PLA possessed a spherical,
“moon-like” shape of ca. 45 ± 10 μm in diameter. In contrast,
amorphous aggregates were formed when PLA−PEG was used
instead (see Figure 2), which resembled those obtained and
described as MPs by Rafat et al.27
An attempt was made to improve the spherical shapes of the
MP (especially for PLA−PEG) through extending the time of
dissolution of PLA and PLA−PEG in chloroform. It was
observed that after 24 h of mixing, as opposed to 3 h as
previously described, the MP of PLA−PEG took on a more
spherical appearance, yet large aggregates were still present.
Other modifications included altering the proportions of the
solutions applied (the water and organic solutions during the
fabrication of the emulsions), further homogenization on a
mechanical mixer when preparing the emulsions, and a
stabilization phase (see Section 2.3). These brought about
significant improvement in MP formation (Figures 3 and 4); the
samples exhibiting diameters of 27.4 ± 6.7 μm for MP PLA/
PVA-AMI and 31.9 ± 7.0 μm for MP PLA−PEG/PVA-AMI. In
terms of the medical application, MP with diameters of up to 40
μm are suitable for use in suspensions intended for the injection
or in the form of an aerosol for respiratory ailments. In light of
this, research efforts continued as a result of the MP fabricated
through the optimized methodology.
FTIR spectroscopy was performed to confirm the successful
loading of MP PLA/PVA and MP PLA−PEG/PVA with AMI.
Measurements were taken in the range of 4000−600 cm−1, and
Figure 5 provides the details of wavelengths from 2250 to 600
cm−1 in order to clearly show the individual FTIR spectra.
Regarding the PLA−PEG/PVA sample without loaded MP,
−CHbending vibration peaks are visible at 1359 and 1310 cm−1,
while that for −CH2 appears at 1450 cm−1. Comparing the
results with the neat PEG spectra28 revealed that these peaks
indicated the presence of PEG grafts in PLA; note that the
occurrence of PLA methyl groups and PEG methylene groups
implies that PLA−PEG copolymerization could have taken
place. The existence of ester groups is confirmed by a peak at
1749 cm−1 (CO stretching vibrations).
PLA-/PVA-based materials have a characteristic peak at 1750
cm−1 (CO stretching vibrations) and ∼1090 cm−1 (a C−O
stretch contributing to alcohols).29 The other absorbance peaks
pertained to −CH bending regions at ∼1450 cm−1 (−CH3
asymmetric) and ∼1360 cm−1 (−CH3 symmetric).30 MP PLA/
PVA and MP PLA−PEG/PVA demonstrated absorption peaks
in the same regions (wavelengths).
The characteristic absorption band for AMI sulfate (as a
powder standard) is observed in the range 1250−900 cm−1.31
The peaks reaching a maximum in this region at approximately
1100 cm−1 relate to the presence of a sulfate counter-ion (SO4
2−
asymmetric stretching vibrations). The absorption band
exhibited between 1200 and 1000 cm−1 represents the C−O
stretching bands of carbohydrates.32 Lastly, the peak at 650 cm−1
corresponds to N−H single bond stretching vibrations.
Comparing the spectra for AMI and MP prior to and following
encapsulation revealed that characteristic bands for AMI were
masked by the components of the polymers, meaning that visible
changes were only seen at 650 cm−1.
Elemental analyses of the loaded and unloaded MP were
performed to determine the composition of the drug delivery
systems. In the case of EDXRF (Table 3), it was found that all
the samples contained an approximate amount of C, H,O, andN
elements (as a sum). The reference of pure AMI used for
modification purposes contained approx. 12% w/w of S, due to
the AMI sulfate salt antibiotic loaded. The remaining materials
under investigation did not contain S, as a consequence of AMI
bonding with the polymermatrix and thematerials being washed
after fabrication, whereby sulfates were removed. Every type of
Table 2. GPC Results for the Synthesized PLA and PLA−
PEGa
sample Mw (g/mol) Mn (g/mol) Mp (g/mol) D̵ (−)
PLA 5200 3000 4600 1.73
PLA−PEG 3900 2800 3500 1.39
aMwweight average molar mass; Mnnumber average molar mass,
Mpmolecular weight of the highest peak; and D̵polydispersity
index (D̵ = Mw/Mn).
Figure 2. SEM images of fabricated MP based on the given methodology:27 PLA/PVA-AMI (left) and PLA−PEG/PVA-AMI (right).
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MP contained Al at a similar level (approx. 2% w/w), potentially
caused by the apparatus employed to prepare them; a
characteristic of the pure AMI standard sample was a lack of
Al. The portion of elements such as Ca, S, K, and Cl in all the
analyzed samples was negligible, below the LOQ (<0.5% w/w).
In addition, no Sn was detected, as present in the catalyst during
polycondensation. Three samples (MP PLA/PVA, MP PLA−
PEG/PVA, and PLA−PEG/PVA-AMI) exhibited Mg at
approximately the level of quantification (0.5% w/w), and one
sample (AMI) showed 1% w/w.
In order to gauge the content of single elements (N, C, H, and
S), the Arc Flash method was applied (Table 4). In
consideration of the S present, the results obtained were largely
in agreement with EDXRF analysis. It was observed that the
materials loaded with AMI were characterized by a higher
content of nitrogen. As for the MP loaded with AMI, nitrogen
content increased by ca. 1.2% w/w for both types of MP (PLA/
PVA-AMI and PLA−PEG/PVA-AMI) in comparison to the
unloaded MP. These results suggest the presence of AMI after
drug loading had taken place, as indicated by the amino groups
in the AMI molecule. The amounts of C and H were similar for
the loaded and unloadedMP, at 49%w/w (C) and 5%w/w (H).
According to the results of BET analysis (Table 5), the MP
PLA−PEG/PVA-AMI were characterized by a slightly greater
surface area (1.929 m2/g) than PLA/PVA-AMI (1.161 m2/g),
arising through the more irregular structure of MP PLA−PEG/
PVA-AMI (see Figure 4). Additionally, the mean pore diameter
of the PLA−PEG-based MP was approximately 14 nm less than
that for PLA-based ones.
The thermal stability of the MP was investigated by analyzing
TGA. The findings (Figure 6, Table 6) revealed that the
fabricated MP had the highest rates for mass loss at 294 and 299
°C for PLA/PVA-AMI and PLA−PEG/PVA-AMI, respectively.
In the case of MP PLA/PVA-AMI, the temperature of
degradation (183 °C) occurred 17 °C lower than that for MP
PLA−PEG/PVA-AMI (Figure 6, peak 1). It is worth noting that
the melting points of the materials employed in fabricating the
MP were in the range of 160−200 °C (PLA5000g/mol = 160 °C,
PVA10,000g/mol = 200 °C, and AMI = 203 °C). According to the
literature, a slight loss in mass at 50−150 °C was caused by the
evaporation of highly volatile components.33 Loss in mass at ca.
300−400 °C indicated the decomposition of PLA.34 In contrast,
the PVA decomposed at 400−450 °C.33 The thermal
decomposition of PEG began at approximately 240 °C,35 and
AMI probably decomposed at 200 °C.
Figure 3. SEM images of the PLA/PVA-AMI particles.
Figure 4. SEM images of the PLA−PEG/PVA-AMI particles.
Figure 5. FTIR spectra for the fabricated MP before and after being
loaded with AMI.
Table 3. Results of Elemental Analyses (EDXRF) of the
Materials in the Form of MP
sample CHON (%)a Al (%) S (%) Mg (%)
MP PLA/PVA 96.80 2.38 0.52
MP PLA/PVA-AMI 97.90 2.00
MP PLA−PEG/PVA 96.50 2.34 0.58
MP PLA−PEG/PVA-AMI 96.30 2.16 0.54
AMI 86.40 12.60 1.00
aweight in percent.
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The temperatures corresponding to 5, 10, and 50% w/w of
mass loss for the samples were established (ΔT5%, ΔT10%, and
ΔT50%, respectively). It was found that MP PLA−PEG/PVA-
AMI exhibited the greatest thermal stability; its temperatures of
degradation for specified points of mass loss were higher by
approx. 8−15 °C in comparison with MP PLA/PVA-AMI.
These results proved that the fabricated MP possessed thermal
stability, making it possible to further reprocess them with other
techniques, for example, with the aim of obtaining a different
kind of material.
In relation to antimicrobial properties (Table 7), the findings
showed that both types of MPs (PLA/PVA-AMI and PLA−
PEG/PVA-AMI) exerted an antimicrobial effect against most of
the investigated strains (except E. faecalis). Interestingly, MP
PLA/PVA-AMI demonstrated better activity against S. aureus
and P. aeruginosa strains (approximately twice that of PLA−
PEG/PVA-AMI). This suggests that adding the copolymer
PLA−PEG diminished the antimicrobial properties through
Table 4. Results of Elemental Analyses (Arc Flash) of the Materials in the Form of MP
sample N ± SDa (%)b C ± SD (%) H ± SD (%) S ± SD (%)
MP PLA/PVA 1.84 ± 0.41 49.17 ± 0.28 5.81 ± 0.23
MP PLA/PVA-AMI 3.06 ± 0.55 47.68 ± 0.74 5.52 ± 0.20
MP PLA−PEG/PVA 2.92 ± 0.66 49.26 ± 0.35 5.93 ± 0.29
MP PLA−PEG/PVA-AMI 4.14 ± 0.26 49.319 ± 0.044 5.17 ± 0.38
AMI 8.114 ± 0.010 30.18 ± 0.22 6.364 ± 0.072 11.5 ± 1.2
aSDthree independently prepared material samples, analyzed twice. bweight in percent.








total pore volume (p/
p0 = 0.990) (cm
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Figure 6. Thermogravimetry and differential thermogravimetry curves for MP PLA/PVA-AMI (upper) and MP PLA−PEG/PVA-AMI (lower).
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possible interactions with the functional groups of AMI, causing
changes in the mechanism of treatment and inhibition of drug
action. TheMPs without AMI were characterized by an absence
of antimicrobial activity against the bacterial strains.
Further investigation included estimation of the % EE (eq 2)
and % LE (eq 3) of the MP. The results presented in Table 8
show that PLA−PEG/PVA-AMI demonstrated approximately
twice as high % EE (32%) and three times as high % LE (10.7%).
This could have been due to enhancement of the amphiphilic
nature of the material through adding PEG, potentially leading
to a heightened affinity of AMI for the polymer matrix. However,
the diameters of inhibition zones (Figure 7) were smaller in
comparison with PLA/PVA-AMI, which lends support to the
study previously described on reduction in antimicrobial
properties through applying the copolymer PLA−PEG instead
of PLA.
As mentioned earlier, only a few studies on AMI
encapsulation in a synthetic polymer (PLGA) were found in
the literature. Compared to the findings from the literature on
the EE of a PLGA system loaded with AMI (76.77± 3.81%),9,16
the values summarized in Table 8 of this work are lower. In the
methodology presented here, however, a significant excess of the
drug was used during preparation of the MP (W1 solution) due
to the greater affinity of AMI to the aqueous phase; nevertheless,
the low cost of AMI means that there is no significantly increase
in expenditure on materials. A notable aspect, though, is that the
LE, calculated as μg of AMI per 1 mg of the polymer, was
determined at the following levels: 36.5 ± 1.5 μg/mg for the
PLA-based MP and 106 ± 32 μg/mg for PLA−PEG-based MP.
These values were higher than those recorded by Sabaeifard et
al. (26.0 ± 1.3 μg/mg nanoparticles).16 A study by Prior et al.36
proposed PLA/PLGA MP loaded with a different aminoglyco-
side antibioticgentamicin, reporting a maximal LE of 8.3 mg/
g for PLA/PLGA and only 3.7 mg/g for PLA. These examples
show the difficulties that exist in fabricating effective drug
delivery systems with polar active substances. The findings
described herein prove that the procedure proposed and
described for fabricating MP guarantees a higher LE.
Considering the in vitro release of AMI (Figure 8 and Table
S1), the total amounts of antibiotic released from the polymer
matrix (mg/g) after 63 days (CR, eq 1) were, respectively, 1.22
± 0.10 mg/g (% CR = 3.3% w/w, where % CR corresponds to
the amount of drug dispensed over a specific time per amount of
Table 6. Results of TGA Analysis for the MP; the Peak Numbers According to Figure 6a


















MP PLA/PVA-AMI 183 294 356 94.6 356 422 498 2.0 96.6 236 255 294
MP PLA−PEG/PVA-AMI 200 299 343 87.5 343 381 400 4.3 91.8 251 267 302
aTionset temperature; Tmtemperature corresponding to the maximum rate of mass loss; Tffinal temperature; Δwmass loss in the range
Ti−Tf; Δwfintotal mass loss; and ΔT5%, ΔT10%, and ΔT50%temperature corresponding to 5, 10, and 50% of sample mass loss, respectively.
Table 7. Antibacterial Activity of the Fabricated MP
width of the inhibition zone ± SDa (mm)
sample S. aureus E. coli E. faecalis P. aeruginosa K. pneumoniae
PLA/PVA-AMI 8.0 ± 0.0 8.5 ± 0.5 0.0 6.5 ± 0.5 10.0 ± 0.0
PLA/PVA 0.0 0.0 0.0 0.0 0.0
PLA−PEG/PVA-AMI 3.5 ± 0.5 5.5 ± 0.5 0.0 3.0 ± 0.0 7.0 ± 0.0
PLA−PEG/PVA 0.0 0.0 0.0 0.0 0.0
AMI 16.5 ± 0.5 16.5 ± 0.5 11.0 ± 0.0 19.0 ± 0.0 18.0 ± 0.0
aSDthree independently prepared material samples, analyzed three times.
Table 8. EE and LE of the MP Loaded with AMI (Based on
Eq. 1 and 2)
sample EE ± SDa (%) LE ± SD (%)
PLA/PVA-AMI 16.3 ± 1.3 3.65 ± 0.15
PLA−PEG/PVA-AMI 32.0 ± 4.8 10.7 ± 3.3
aSDthree independently prepared material samples, analyzed three
times.
Figure 7. Examples of inhibition zones (against E. coli): (A)pure PLA/PVA; (B)PLA/PVA-AMI; (C)pure PLA−PEG/PVA; (D)PLA−
PEG/PVA-AMI; and (E)pure AMI.
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drug loaded, eq 2) for PLA/PVA-AMI and 5.19± 0.21 mg/g (%
CR = 4.0% w/w) for PLA−PEG/PVA-AMI. After the first 15
min of testing, the amounts of AMI released equaled 0.56± 0.18
mg/g (% CR = 1.5% w/w) for PLA/PVA and 2.81 ± 0.38 mg/g
(% CR = 2.2% w/w) for PLA−PEG/PVA.
It is worth noting that the proposed polymer systems
provided AMI release even after 2 months, making them
suitable for long-term application. In comparison, the
established release times of AMI in the literature were 24 h
from PLGA16 and 12 h from nanoparticles prepared from
Eudragit RS 100 and RL 100.17
In following investigation, the results obtained were applied to
determine the theoretical kinetics of AMI release from the
polymer matrix. Table 9 summarizes the established release
constant K, as calculated by different mathematical models.
According to the value for the correlation coefficient (R2)
between findings from analysis of real-word samples and
theoretical ones (determined by mathematical assumption), it
was clear that the Korsmeyer−Peppas model showed the best
match for both forms of fabricated MPs (PLA/PVA-AMI and
PLA−PEG/PVA-AMI). Furthermore, based on the value for
diffusion convection (n, eq 8), it was specified that the
mechanism of AMI release was based on Fickian diffusion (n
≤ 0.45). This evidences the rapid release of the drug in the first
few hours of analysis. This phenomenon was expected due to the
stronger affinity of AMI to the aqueous solution (during
emulsification). Consequently, the most rapid drug release in
the first 3 h was associated with the presence of AMI molecules
on or trapped near the surface of the MP. The slower release of
AMI in subsequent hours was due to the presence of drug
molecules in the deeper layers of the MP, as well as polymer
erosion and hydrolytic bulk degradation.12,16 Rapid release of a
drug followed by a continual, slower trend is preferred for
materials with antimicrobial applications.16
Despite the similar fit of the HiguChi model (eq 7), it was
found that the obtained release constants in the given series of
measurements varied greatly from one another (CV > 100%,
where CVcoefficient of variation). Consequently, the
assumptions of the authors were not met.
A GPC study after 56 days of MP exposure in PBS solution
was also carried out. Samples were treated under the same
conditions as in the in vitro release test. Subsequently, 1 mL of
the liquid fraction with suspended MP was collected for each of
the prepared samples. To prove the occurrence of MP
degradation, reference samples of MP, that is, without exposure
to the PBS solution, were also prepared and tested by GPC.
Table 10 summarizes the results. Based on the determined
parameters, it was found that both types of MPs exhibited
reduction in Mw during the degradation test. In the case of MP
PLA/PVA-AMI, the value forMw after 56 days of exposure was
2.1 times lower (in comparison to the reference sample, Mw
degradation = 52%). The greatest reduction inMw was observed
for PLA−PEG/PVA-AMI, where Mw was 3.6 times lower than
that for the sample not exposed to the PBS solution (Mw
degradation = 73%). The observed loss in mass loss indicates
a degradation of all the fabricated materials, which is a positive
effect and provides for the possibility of release of any trapped
drug.
Figure 8. AMI release from MP PLA/PVA and MP PLA−PEG/PVA (SDthree independently prepared material samples).
Table 9. Release Constants (K) and Correlation Coefficients (R2) Determined by Mathematical Models
0-order release I-order release HiguChi model Korsmeyer−Peppas model
sample K0 ± SD
a R2 KI ± SD R2 KH ± SD R2 KKP ± SD R2
MP PLA/PVA-AMI 0.262 ± 0.039 0.9457 0.388 ± 0.082 0.7340 0.245 ± 0.031 0.9740 0.564 ± 0.046 0.9973
MP PLA−PEG/PVA-AMI 0.324 ± 0.014 0.8859 0.539 ± 0.040 0.8158 0.300 ± 0.013 0.9566 0.631 ± 0.028 0.9996
aSDthree independently prepared material samples, analyzed three times.











MP PLA/PVA_0a 5800 3800 4800 1.53
MP PLA/PVA-AMI (after 56
days)
2800 1500 750 1.75
MP PLA−PEG/PVA_0 4500 3300 3300 1.36
MP PLA−PEG/PVA-AMI (after
56 days)
1234 975 882 1.79
aSample_0reference sample (without immersion in the PBS
solution), Mwweight average molar mass; Mnnumber average
molar mass, Mpmolecular weight of the highest peak; and D̵
polydispersity index (D̵ = Mw/Mn).
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://doi.org/10.1021/acs.molpharmaceut.1c00193
Mol. Pharmaceutics 2021, 18, 2986−2996
2994
The investigation over the long-term for determining the
kinetics of AMI release and degradation of the fabricated
materials was necessary due to the expected burst ef fect indicated
by the hydrolytic degradation of PLA and relaxation of the
polymer chain.
4. CONCLUSIONS
Encapsulating AMI in synthetic polymers such as PLA or PLA−
PEG is a challenge, due to the polarity of AMI, also in
comparison to other aminoglycosides like gentamicin or
tobramycin. This phenomenon has a significant impact on the
drug LE through partial entrapment of the drug in the polymer
phase.
Herein, a new emulsification method is proposed with low-
molecular-weight PLA or PLA−PEG supplemented with PVA
for AMI encapsulation. The resultant MPs were characterized as
having diameters of less than 30 μm. The values of LE for the
fabricated MP, determined as μg of AMI per 1 mg of the
polymer, were as follows: 36.5 ± 1.5 μg/mg for PLA/PVA-AMI
and 106± 32 μg/mg for PLA−PEG/PVA-AMI. The most rapid
AMI release in both cases (MP PLA/PVA and MP PLA−PEG/
PVA) was observed within the first 3 h with release kinetics
based on the Korsmeyer−Peppasmodel. The remaining amount
of AMI continued to be gradually released even after 63 days.
The fabricated materials exhibited high antimicrobial activity
against the S. aureus, E. coli, P. aeruginosa, and K. pneumoniae
bacterial strains. The AMI-loaded MPs did not act against E.
faecalis, unlike neat AMI. Additionally, due to the high thermal
stability of the prepared MP, the potential exists to reprocess
them further, for example, by 3D printing tailored, functional
drugs in a form desirable for therapy.
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